|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed BE tissues for mRNAs that associate with BE progression and identified one that affects the stabilization of p53.
|
31715145 |
2020 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in key genes including TP53 occur early in the neoplastic progression sequence of Barrett's esophagus, whereas chromosomal amplification resulting in oncogene activation occurs as a critical late event.
|
31021922 |
2019 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 losses were detected in concurrent-BE but not earlier in preprogression-BE tissues of patients who developed DAC.
|
31001805 |
2019 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the use of p53 immunostaining as an adjunct to routine clinical diagnosis for dysplasia in BE patients.
|
30911864 |
2019 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of p53 IHC significantly improves the histological assessment of BO biopsies, even within a group of dedicated GI pathologists.
|
29314176 |
2018 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this case-control sample set, TP53 mutations in BE tissues increased the adjusted risk of progression 13.8-fold (95% confidence interval, 3.2-61.0) (P < .001).
|
29608884 |
2018 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that p53 protein accumulation, detected by immunohistochemistry in aggregates of cells, is a significant predictor of malignant progression in patients with BM.
|
28226185 |
2017 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant p53 expression in BE patients appeared to be associated with a significantly increased risk of neoplastic progression for both non-dysplastic and LGD BE patients.
|
29059206 |
2017 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutational investigation revealed distinct pathways activated between EAC tissues with or without TP53 mutations compared with Barrett's disease.
|
28751461 |
2017 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to identify biomarkers of active HPV infection in Barrett's metaplasia, (BM)/BD/OAC by immunohistochemical staining (IHC) of formalin-fixed paraffin embedded (FFPE) tissue for aberrations of p53 and the retinoblastoma (pRb) pathway, which are targets for the viral oncoproteins, E6/E7, respectively.
|
28722212 |
2017 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the used markers, those that map nearby TP53 gene were the most discriminant between metaplastic and dysplastic BE.
|
29066320 |
2017 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although p53 is a promising marker for identifying high-risk BE patients, it is not recommended for routine use at present; additional studies are needed to address questions regarding case selection, interpretation, integration with morphologic diagnosis, and impact on clinical outcome.
|
28248814 |
2017 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results showed that: (i) early BE molecular alterations are mainly localized proximal to, or within, TP53 gene; (ii) LOH events present in cfDNA not only retrace the time-matched biopsy profile but better represent the total alterations of the BE epithelium.
|
27234667 |
2016 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to provide an unbiased extraction of the knowledge from the literature, a text-mining methodology was used to select genes that are involved in the BE progression, with the top candidate genes found to be TP53, CDKN2A, CTNNB1, CDH1, GPX3, and NOX5.
|
27415609 |
2016 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 IHC on tissue sections and FISH on brush cytology specimens were evaluated for 116 BE patients with respect to the different histological stages.
|
25284618 |
2015 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next-generation sequencing panels for detection of TP53 and possibly combined mutations in other genes, such as APC and CDKN2A, may be useful in the clinical setting to improve dysplasia and cancer surveillance in patients with Barrett's esophagus.
|
26068095 |
2015 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mutations often occurred early in Barrett's esophagus progression, including in non-dysplastic epithelium.
|
26192918 |
2015 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent somatic mutations in the tumor suppressor genes CDKN2A and TP53 were recently reported in EA tumors, while somatic alterations at 9p (CDKN2A) and 17p (TP53) have been implicated as predictors of progression from BE to EA.
|
25280564 |
2014 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cdx2, mucin (MUC) series (MUC2, MUC5AC and MUC6), p53 and E-cadherin expression in Barrett's esophagus and adenocarcinoma specimens were examined by immunostaining.
|
23382633 |
2013 |
|
Barrett Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
|
19638963 |
2009 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulation of p53 was seen several years before development of HGD/EAC, and may therefore be an early marker in BE at a stage when dysplasia is not yet detected.
|
18334729 |
2008 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
|
17849424 |
2008 |
|
Barrett Esophagus
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
|
17982662 |
2007 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Esophageal biopsies from 243 patients with BE were evaluated at baseline for TP53 and CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing; loss of heterozygosity (LOH); methylation-specific PCR; and flow cytometry.
|
17326708 |
2007 |
|
Barrett Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We concluded that p53 is insufficient as a single marker for Barrett's esophagus monitoring but may be useful as part of a panel due to its high specificity.
|
17982662 |
2007 |